Why Supernus Pharmaceuticals Stock Topped the Market Today
It's effecting a "merger of equals" with a peer.
Overview
Supernus Pharmaceuticals (NASDAQ: SUPN) began the stock trading week on a high note, announcing a major merger alongside its latest quarterly earnings release.
Investors ultimately decided to be cautiously optimistic about these developments; after the stock rose by as much as 16%, it settled down to close 3% higher. That bettered the 1.5% gain of the bellwether S&P 500 index.
Details
Supernus revealed it has entered into a definitive agreement to combine with peer Indivior Pharmaceuticals (NASDAQ: INDV). This will be undertaken in a tax-free, all-stock merger.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.